BioCentury
ARTICLE | Company News

AZN files Crestor NDA; discontinues Viozan

June 27, 2001 7:00 AM UTC

AstraZeneca (AZN) filed for U.S. and European approval of its Crestor rosuvastatin to manage hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. The statin was licensed from Sh...